Literature DB >> 6156899

Converting enzyme inhibition and the kidney.

L G Meggs, N K Hollenberg.   

Abstract

We review information on the renal response to converting enzyme inhibition, and attempt to evaluate the evidence that a reduction in angiotensin II formation is responsible for the renal response. There is little response to converting enzyme inhibitors in animals or man when the renin-angiotensin system is suppressed by a literal sodium intake. With restriction of sodium intake, an increase in renal blood flow occurs; because a quantitatively similar response occurs to the angiotensin II analogs it is likely that the response reflects reversal of the local action of angiotensin II. In other settings it is not yet clear whether the renal response to converting enzyme inhibitor reflects only a reduction in angiotensin II formation or an additional action such as potentiation of the local actions of bradykinin or enhanced prostaglandin formation. Because these agents induce a potentiated increase in renal blood flow in the patient with essential hypertension, and with it an increase in glomerular filtration rate and sodium excretion in some patients, despite a fall in arterial pressure these questions have considerable importance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6156899     DOI: 10.1161/01.hyp.2.4.551

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  The effects of combined angiotensin converting enzyme inhibition and beta-adrenoceptor blockade on plasma renin activity in anaesthetized dogs.

Authors:  D Cambridge; M V Whiting; L J Butterfield; G Allan
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

2.  Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure.

Authors:  S K Mujais; F M Fouad; S C Textor; R C Tarazi; E L Bravo; N Hart; R W Gifford
Journal:  Br Heart J       Date:  1984-07

Review 3.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 4.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

5.  Cardiac and renovascular effects in the anaesthetized dog of BW A575C: a novel angiotensin converting enzyme inhibitor with beta-adrenoceptor blocking properties.

Authors:  D Cambridge; M V Whiting; G Allan
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

6.  Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension.

Authors:  R A Sánchez; E Marcó; H B Gilbert; P Raffaele; M Brito; M Giménez; L I Moledo
Journal:  Drugs       Date:  1985       Impact factor: 9.546

7.  [Angiotensin-converting enzyme inhibition: direct and indirect mechanisms].

Authors:  K O Stumpe
Journal:  Klin Wochenschr       Date:  1985-09-16

8.  Specific desensitization of the canine renal vasculature to angiotensin II despite cyclo-oxygenase inhibition.

Authors:  L G Meggs; R W Katzberg; P DeLeeuw; N K Hollenberg
Journal:  Yale J Biol Med       Date:  1985 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.